Bladen County Receives $26.6 Million from DuPont and Chemours Settlement

Cape Fear River Watch alleges Chemours has failed to meet pollution limits agreed upon in a 2019 consent order, claiming the company's groundwater and air emissions controls are inadequate. Chemours disputes these claims, stating it has spent $1.2 billion complying with the order. The environmental group filed a formal notice, citing high levels of PFAS in surface water and groundwater around the plant.

Chemours (CC) shares rose 3.10% after agreeing to a settlement with North Carolina and nearby communities over emissions. The stock is at $14.98, down 29.24% over 90 days. Analysts view it as undervalued at a fair value of $19.78, citing growth in advanced materials and cost optimization. However, PFAS liabilities and regulations pose risks.

A U.S. judge ruled that 3M, DuPont, Honeywell, and others must face claims from Connecticut firefighters over PFAS exposure in protective gear. The lawsuit alleges the gear, containing 3M's Scotchlite and DuPont's Kevlar, increased cancer risks. The judge allowed the case to proceed, permitting damages and medical monitoring claims. The companies argue the gear served its protective function. PFAS makers face broader scrutiny, with prior settlements totaling over $11 billion.

Chemours (CC), DuPont, and Corteva agreed to a US$455 million settlement over PFAS emissions, shared equally. Payments will span 15 years, adjusting cost accounting under a US$4 billion cap. Chemours aims to recover profits by 2029, with revenue and earnings projections of US$6.6 billion and US$686.0 million, respectively, despite current losses. Analysts highlight operational execution and PFAS liability management as key factors.

Chemours, DuPont, and Corteva agreed to a $455 million settlement over PFAS contamination claims. Chemours will pay $50 million in the next year, with the total paid over 15 years. The companies will split the cost equally, and the settlement addresses past and future liabilities related to Fayetteville Works and other sites.

Chemours (CC) reported Q2 with net loss narrowing to $274M (vs. $380M YoY) and free cash flow up 128%. Sales were flat at $1.6B, but volumes fell 4%. TiO2 prices rose 5% YoY, and leverage improved to 4.4x EBITDA. Q3 sales guidance is down 5% to flat. CC trades at a forward P/E of 7.11.